enGene Therapeutics (ENGN) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sutro Biopharma (STRO) has outperformed enGene Therapeutics (ENGN) over the past year, gaining 2.4% versus a loss of 75.0%. Sutro Biopharma is the larger company by market cap ($142.8 million vs $116.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | STRO |
|---|---|---|
| Share price | $1.74 | $8.60 |
| Market cap | $116.61M | $142.77M |
| 1-day change | -1.14% | -1.38% |
| YTD return | -80.73% | -25.67% |
| 1-year return | -75.00% | +2.38% |
| 5-year return | — | -94.68% |
| EPS (TTM) | $-2.07 | $-12.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $102.48M |
| Revenue growth (YoY) | — | +65.18% |
| Net income (latest FY) | $-117.30M | $-191.09M |
| Operating margin | — | -154.53% |
| Net margin | — | -186.45% |
| 52-week high | $12.25 | $43.85 |
| 52-week low | $1.40 | $7.15 |
| Distance from 52-week high | -85.80% | -80.39% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +146.55% | +419.65% |
| Average volume | 1.12M | 304.90K |
| Shares outstanding | 67.02M | 16.60M |
| Employees | 81 | 129 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed ENGN by 77.4 percentage points over the past year.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 129 employees
ENGN vs STRO FAQ
Which is bigger, enGene Therapeutics or Sutro Biopharma?
Sutro Biopharma (STRO) is larger, with a market capitalization of $142.77M compared with $116.61M for enGene Therapeutics (ENGN).
Which stock has performed better over the past year, ENGN or STRO?
STRO returned +2.38% over the past 12 months, compared with -75.00% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.